Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 15/20 | 0.55 |
| ▸ | CDK4 | P11802 | 3/20 | 0.40 |
| ▸ | CCND1 | P24385 | 3/20 | 0.40 |
| ▸ | PRKACA | P17612 | 3/20 | 0.40 |
| ▸ | PRKACG | P22612 | 3/20 | 0.40 |
| ▸ | PRKACB | P22694 | 3/20 | 0.40 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.38 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | PRKCG | P05129 | 1/20 | 0.38 |
| ▸ | PRKCB | P05771 | 1/20 | 0.38 |
| ▸ | PRKCA | P17252 | 1/20 | 0.38 |
| ▸ | PRKCH | P24723 | 1/20 | 0.38 |
| ▸ | PRKCI | P41743 | 1/20 | 0.38 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.38 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.38 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7031130 | 0.95 | TOP1 (0.54) | TOP1CDK4CCND1PRKACAPRKACG | |
| SCHEMBL6736290 | 0.93 | TOP1 (0.57) | TOP1CDK4CCND1PRKACAPRKACG | |
| SCHEMBL7024637 | 0.93 | TOP1 (0.51) | TOP1CDK4CCND1PRKACAPRKACG | |
| SCHEMBL5870241 | 0.92 | TOP1 (0.51) | TOP1CDK4CCND1PRKACAPRKACG | |
| SCHEMBL6316287 | 0.90 | TOP1 (0.59) | TOP1CDK4CCND1PRKACAPRKACG | |
| SCHEMBL5870245 | 0.88 | TOP1 (0.51) | TOP1CDK4CCND1PRKACAPRKACG | |
| SCHEMBL7861913 | 0.87 | TOP1 (0.65) | TOP1PRKCA | |
| SCHEMBL7031134 | 0.85 | TOP1 (0.55) | TOP1CDK4CCND1PRKACAPRKACG | |
| SCHEMBL6736646 | 0.84 | TOP1 (0.52) | TOP1CDK4CCND1PRKACAPRKACG | |
| SCHEMBL7027394 | 0.83 | TOP1 (0.45) | TOP1CDK4CCND1PRKACAPRKACG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138377-B2 | Topoisomerase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-21 | — | — | US | disclosed |
| US-6677450-B2 | N12, N13-BRIDGED SUGAR DERIVATIVES OF INDOLYLOPYRROLOCARBAZOLES, USEFUL IN INHIBITING THE PROLIFERATION OF TUMOR CELLS | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-13 | — | — | US | disclosed |
| US-6653290-B2 | Sugar derivatives of indolocarbazoles; exhibit topoisomerase-I activity | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-25 | — | — | US | disclosed |
| US-20030203860-A1 | Substituted sugar derivatives of indolopyrrolocarbazoles, useful in inhibiting the proliferatin of tumor cells | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-30 | — | — | US | disclosed |
| EP-1326875-A2 | TUMOR PROLIFERATION INHIBITORS | Bristol-Myers Squibb Company (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20030083271-A1 | Topoisomerase I selective cytotoxic sugar derivatives of indolopyrrolocarbazoles | BRISTOL-MYERS SQUIBB COMPANY | 2003-05-01 | — | — | US | disclosed |
| US-20020107237-A1 | Topoisomerase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2002-08-08 | — | — | US | disclosed |
| US-20020068705-A1 | Tumor proliferation inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2002-06-06 | — | — | US | disclosed |
| WO-2002028874-A2 | TUMOR PROLIFERATION INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068705-A1 | Tumor proliferation inhibitors | MKI67, TOP1, CCNI | TOP1 2/4885CDK4 19/4885CCND1 27/4885 |
| US-20030083271-A1 | Topoisomerase I selective cytotoxic sugar derivatives of indolopyrrolocarbazoles | TOP1, TOP2A, TOP2B | TOP1 1/4885CDK4 169/4885CCND1 444/4885 |
| US-20030203860-A1 | Substituted sugar derivatives of indolopyrrolocarbazoles, useful in inhibiting the proliferatin of tumor cells | TYMP, MKI67, CCNI | TOP1 5/4885CDK4 7/4885CCND1 80/4885 |
| US-20020107237-A1 | Topoisomerase inhibitors | TOP1, TOP2A, TOP2B | TOP1 1/4885CDK4 119/4885CCND1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.